Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    COVID-19
    COVID-19 Affects Cancer Caregivers, but Here Are Ways to Support Them
    February 19, 2021
    Celebrate Oncology Nurse Leaders During Black History Month
    ONS Leadership
    Celebrate Oncology Nurse Leaders During Black History Month
    February 03, 2021
    Am I Too Shy to Lead?
    Nurse staffing
    Am I Too Shy to Lead?
    January 29, 2021
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    nursing professional development
    Zoom Through Video Job Interviews With These Tips for Applicants and Hiring Managers
    January 22, 2021
    The Case of Concurrent Therapy Concerns
    Treatment side effects
    The Case of Concurrent Therapy Concerns
    December 18, 2020
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Genetics & genomics

    Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer)
    Genetics & genomics

    Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer)

    Lynch syndrome, now referred to as hereditary nonpolyposis colorectal cancer (HNPCC), was first identified in a family in 1895. In 1966, Henry Lynch reported a series of families with colon and other cancers in the Nebraska area. Today, the evidence shows that HNPCC is associated with germline pathogenic variants in the MLH1, MSH2, MSH6, PMS2, and EPCAM genes.

    January 25, 2021
    Genomics Provides Insight on Exceptionally Responding Patients
    Genetics & genomics

    Genomics Provides Insight on Exceptionally Responding Patients

    Patients with cancer who experience unexpected and long-lasting treatment outcomes are considered exceptional responders, but researchers and clinicians had no insight as to why the patients did so well with treatment. Results of a new study now show that genomic characterizations of cancer can uncover genetic alterations that may contribute to the phenomenon, researchers reported in Cancer Cell.

    January 13, 2021
    Genomics May Trick PARP Inhibitors to Treat More Cancers
    Research

    Genomics May Trick PARP Inhibitors to Treat More Cancers

    Turning on the body’s inflammasome with epigenetic therapy may improve the efficacy of PARP inhibitors across multiple tumor types, possibly expanding the therapy’s application to new cancers, researchers reported in Proceedings of the National Academy of Sciences.

    December 23, 2020
    What Is the Role of Genetic Counselors in Cancer Care?
    Genetics & genomics

    What Is the Role of Genetic Counselors in Cancer Care?

    Our understanding of cancer’s genetic components is constantly growing, with new cancer susceptibility genes discovered every year that change how we screen for and treat cancer. Genetics specialists keep up with the latest information and implications of genetic results is and can be a great addition to comprehensive oncology teams.

    December 15, 2020
    Harnessing the Power of Genes
    Genetics & genomics

    Harnessing the Power of Genes

    Since the mapping of the human genome in 2003, genetic testing has rapidly evolved from single-gene tests to more complex profiles that measure multiple genes; it’s now part of standard care for many cancer types. Precision oncology allows clinicians to take patient-specific genomic factors into consideration when making treatment decisions, which can lead to improved outcomes, lower overall cost, and fewer side effects.

    December 01, 2020
    Oncology Nurses Have a Role in Genomics Throughout the Cancer Care Continuum
    Genetics & genomics

    Oncology Nurses Have a Role in Genomics Throughout the Cancer Care Continuum

    Cancer genomics influences all oncology nursing roles. Walking through the cancer care continuum shows how genomics—and oncology nursing—are involved at every level.

    November 26, 2020
    Winning Team Reduces Disparities to Biomarker Testing in First-Ever ONS Hackathon
    Press Releases

    Winning Team Reduces Disparities to Biomarker Testing in First-Ever ONS Hackathon

    The Oncology Nursing Society (ONS) launched its inaugural ONS Hackathon™ on November 9, 2020, a competition designed to identify innovative ways to address challenging issues in the delivery of quality cancer care. Meghan O. Coleman, DNP, CRNP, and Alison McDaniel, BSN, RN, OCN®’s winning project, Evidence-Based Quality Understanding in Pathology, provided ways to solve the problem of unequal access to biomarker and other genetic and genomic testing.

    November 23, 2020
    Get Answers to Your Most Frequently Asked Genomics and Cancer Questions
    Genetics & genomics

    Get Answers to Your Most Frequently Asked Genomics and Cancer Questions

    Approximately 700 members responded to ONS’s 2020 genomics survey, which gauged oncology nurses’ current genomic knowledge, applications in practice, and the specific questions they have about genetics and genomics. Here are the answers to the most frequently asked questions based on the survey responses.

    October 27, 2020
    Breast Cancer Prevention, Screening, Diagnosis, Treatment, Side Effect, and Survivorship Considerations
    Breast cancer

    Breast Cancer Prevention, Screening, Diagnosis, Treatment, Side Effect, and Survivorship Considerations

    In the United States, breast cancer is the most commonly diagnosed cancer in women. One in eight women will develop invasive disease in their lifetime with approximately 270,00 new cases diagnosed in the United States in 2019. Caucasian women have the highest incidence rate, whereas African American women are most likely to die from the disease. The five-year survival rate is 91%, with an estimated 3.8 million breast cancer survivors living in the United States.

    October 15, 2020
    What Is a Genomic Variant?
    Genetics & genomics

    What Is a Genomic Variant?

    The Human Genome Project determined the DNA sequence (order of base pairs) of the entire human genome. Humans are 99.9% identical at the level of base pair ordering, but the 0.1% difference contributes to disease risk. Upon completion of the human genetic blueprint, research turned to identifying and cataloguing genomic variation as well as determining the clinical relevance of variants.

    September 17, 2020
    FDA Approves Pralsetinib for Lung Cancer With RET Gene Fusions
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pralsetinib for Lung Cancer With RET Gene Fusions

    On September 4, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pralsetinib (Gavreto™) for adult patients with metastatic, RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.

    September 10, 2020
    As True Detectives, Genetics Professionals Uncover the Meaning of True or Noninformative Negative Results
    Genetics & genomics

    As True Detectives, Genetics Professionals Uncover the Meaning of True or Noninformative Negative Results

    Patients who watch crime shows think that DNA testing is as simple as taking a cheek swab and getting the results in two minutes so the case is solved at the end of the 42-minute episode. The reality? DNA can be identified from buccal cells in a cheek swab, but results take several weeks to obtain and are not always a simple negative or positive.

    August 18, 2020
    Variants of Unknown Significance
    Genetics & genomics

    Help Patients Understand Genomic Variants of Unknown Significance

    Patients approach genetic testing, either for germline (inherited) or somatic (tumor) alterations, hoping it will provide valuable information about their cancer risk, prognosis, or treatment options. Next-generation sequencing makes it possible to test for panels of 40 or more genes simultaneously. By testing more genes, the possibility of finding an actionable, informative result improves, but so does the chance of having a result with one or more variants of unknown clinical significance.

    July 06, 2020
    Misconceptions About Radioactive Targeted Therapies
    Genetics & genomics

    An Oncology Nurse’s Primer on Genomics and Biomarker Terminology

    With the massive paradigm shift in cancer therapy to precision medicine, the use of biomarkers and biomarker testing has also rapidly evolved to guide treatment selection. However, the terminology used in genomics is complex and inconsistent, and patient advocacy organizations recommend using a common taxonomy to prevent confusion among patients and providers alike. Nurses spend more time with patients and families than any other member of the healthcare team and can reinforce common language and terminology. As a nurse, here are the terms you need to understand.

    June 17, 2020
    Family Risk Factors May Indicate Need for Genetics Counseling Referrals
    Genetics & genomics

    Family Risk Factors May Indicate Need for Genetics Counseling Referrals

    Genetics testing is not just about one family member; the results have implications for an entire family. Results of genetic testing can be confusing, and families often need assistance understanding what it means for them. Genetics counseling before and after testing is very important to help individuals and families understand the results of genetic testing when they are received and over time. 

    May 14, 2020
    What Happens During a Genetics Counseling Session?
    Genetics & genomics

    What Happens During a Genetics Counseling Session?

    When referring patients for genetics counseling and possible testing for hereditary risk, oncology nurses can help relieve their trepidation and anxiety by explaining what to expect during the visit. See the sidebar for key indications for referral.

    March 26, 2020
    Genomic Data Changes Care for Cancer Survivors
    Genetics & genomics

    Genomic Data Changes Care for Cancer Survivors

    Further understanding of the human genome and the proliferation of genetic data has spurred significant advancement in the understanding of the way cancer impacts individuals. To share the crucial work in genetics, the National Institutes of Health (NIH), led by the National Institute for Cancer (NCI), has compiled survivor stories from patients who have benefited from cutting-edge genomic technology. Their stories illustrate and contribute to the ongoing successes brought on by NIH’s genomic efforts.

    March 12, 2020
    World Gets Closer to Identifying Cancer’s Genomic Drivers
    Genetics & genomics

    World Gets Closer to Identifying Cancer’s Genomic Drivers

    Although most cancers contain four to five driver mutations, those drivers remain unknown for about 5% of cancers, according to results of a series of studies examining genomes from 38 different cancer types. The international Pan-Cancer Analysis of Whole Genomes Consortium reported the findings in a collection of 23 articles published in Nature and other affiliated journals.

    February 25, 2020
    How DNA Sequencing Technologies Are Used in Cancer Care, Now and in the Future
    Genetics & genomics

    How DNA Sequencing Technologies Are Used in Cancer Care, Now and in the Future

    Genomic testing identifies germline or inherited DNA changes that increase a person’s cancer risk, and it also can identify or profile the somatic or acquired changes in a tumor that guide selection of appropriate targeted therapies. The latter type of genomic testing is an analysis of DNA sequence information.

    February 20, 2020
    Germline and Somatic Mutations: What Is the Difference?
    Genetics & genomics

    Germline and Somatic Mutations: What Is the Difference?

    Cancer occurs from mutations, or harmful changes from an alteration in a gene’s DNA sequence. Most mutations involve changes in the order of the base pairs, including substitutions, deletions, additions, or shifts. Mutations can be divided into broad categories based on the tissue where they occur.

    January 14, 2020
    Multigene Testing Is Cost Effective for All Women With Breast Cancer
    Genetics & genomics

    Multigene Testing Is Cost Effective for All Women With Breast Cancer

    According to findings from a new analysis published in JAMA Oncology, multigene testing should be expanded to all women with breast cancer and not just those with certain family histories or clinical factors.

    December 20, 2019
    What Is the Difference Between Genetics and Genomics?
    Genetics & genomics

    What Is the Difference Between Genetics and Genomics?

    Genetics versus genomics: Is there a difference? Does it even matter? There is, and it does. In our era of precision medicine, also referred to as individualized or genomic medicine, being able to differentiate the terms is a first step in establishing a foundational understanding of what they mean for cancer care from prevention to treatment.

    November 07, 2019
    Medicare Cancer Screening; ACA Remains Strong; Medicare for All Cost
    Affordable Care Act (ACA)

    Advanced Cancer Screening Coverage; ACA Remains Strong; Medicare for All Cost

    Precision medicine has a been a hot topic in health care for years now, but costs and coverage issues have created challenges to get patients the genetic testing they need at an affordable cost. In a memo from October 29, 2019, the Centers for Medicare and Medicaid Services (CMS) proposed extending Medicare coverage to pay for genetic sequencing tests for certain hereditary types of ovarian and breast cancer.

    November 04, 2019
    FDA Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC

    On August 15, 2019, the U.S. Food and Drug Administration (FDA) granted accelerated approval to entrectinib (RozlytrekTM) for adults and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy.

    August 16, 2019
    Continued Conversation Shows That Nurses Need More Genetics Education
    Genetics & genomics

    Continued Conversation Shows That Nurses Need More Genetics Education

    During the  44th Annual ONS Congress in April 2019, some sessions featured a Continuing the Conversation event following the main session. As a speaker, this might have been the best part for me. It was filled with unexpected, wonderful surprises and great conversations with oncology nursing colleagues.

    July 19, 2019
    NIH All of Us Campaign Celebrates First Anniversary
    Health Policy

    NIH All of Us Campaign Celebrates First Anniversary

    As part of the rising wave of precision medicine initiatives, the National Institutes of Health (NIH) launched the All of Us campaign in 2018. This one-of-a-kind research program aimed to collect data from more than one million Americans, including factors about lifestyle, environment, and biology, to understand impacts on health and well being. The information would help researchers to better understand the individual nature of health to ultimately inform decisions about delivering precision medicine.  

    July 11, 2019
    Beta Data Browser Puts Precision Medicine Cohort at Researchers’ Fingertips
    Oncology nurse scientist

    Beta Data Browser Puts Precision Medicine Cohort at Researchers’ Fingertips

    The future of cancer care is here: precision medicine has led to many of today’s newest cancer treatments and has made incredible progress since former President Barak Obama first announced the U.S. Precision Medicine Initiative (PMI) in 2015.

    June 27, 2019
    U.S. Rep Cummings Introduces Henrietta Lacks Enhancing Cancer Research Act
    Health Policy

    U.S. Rep Cummings Introduces Henrietta Lacks Enhancing Cancer Research Act

    After recent a best-selling book-turned-movie detailed her story, Henrietta Lacks’ extraordinary impact on cancer research continues to become common knowledge to more people. However, many more are still unaware of how her story, struggle with cancer, and tumor cells changed the face of cancer care. For that reason, Representative Elijah Cummings (D-MD), along with a congressional delegation from both chambers, introduced legislation to both honor her role in history and improve access to medical research to traditionally underrepresented groups.

    May 17, 2019
    New Genetics Service Delivery Models Help Patients Access Genetic Counseling
    Genetics & genomics

    New Genetics Service Delivery Models Help Patients Access Genetic Counseling

    As genetic and genomic testing become more common—and complex—in cancer diagnosis and treatment decisions, more efficient and accessible ways of providing comprehensive genetic care are needed. In their article in the February 2019 issue of the Clinical Journal of Oncology Nursing, Pierle and Mahon discussed the findings from their literature review, specifically pertaining to genetics care services across the cancer continuum, patient and system barriers to accessing care, new service delivery models, and oncology nurses’ role in providing comprehensive cancer genetics care services.

    May 07, 2019
    Guidelines Insufficient for Prostate Cancer Germline Genetic Testing
    Research

    Guidelines Insufficient for Prostate Cancer Germline Genetic Testing

    According to researchers, only 43.8% of positive genetic variants detected in men with prostate cancer had corresponding recommendations for germline testing in National Comprehensive Cancer Network (NCCN) guidelines. The findings were published in JAMA Oncology.

    April 17, 2019
    The Case of the Belated BRCA Test
    Genetics & genomics

    The Case of the Belated BRCA Test

    Eighteen months after completing surgical debulking and chemotherapy for stage III high-grade serous ovarian cancer, 56-year-old Lily experienced a rising CA-125 level. At her oncologist’s recommendation, Lily started an aromatase inhibitor, but it did not stop the rising tumor marker. After she began experiencing symptoms of bloating and mild abdominal pain, Lily and her oncologist decided to proceed with second-line chemotherapy. As she left the office, Lily remarked that she did not complete genetic testing when she was originally diagnosed because she does not have any children or a family history of ovarian cancer and she was concerned that her insurance would not cover the testing.

    April 16, 2019
    ONS Congress

    What Genetics Means in Hereditary Cancer

    Genetic testing and genetics care are playing an increasingly important role in oncology and are continually evolving, Suzanne M. Mahon, DNSc, RN, AOCN®, AGN-BC, of the School of Nursing at Saint Louis University in Missouri, said during a session on Thursday, April 11, 2019, at the ONS 44th Annual Congress in Anaheim, CA.

    April 11, 2019
    Biosimilars, Oral Agents, and Drugs Targeting Genetic Mutations Are Creating a Paradigm Shift in Cancer Treatment
    Genetics & genomics

    Biosimilars, Oral Agents, and Drugs Targeting Genetic Mutations Are Creating a Paradigm Shift in Cancer Treatment

    New treatment options continue to emerge for diseases that until recently had limited, if any, treatment choices. Nurses are seeing more changes in the way treatment regimens come together, biosimilars are presenting viable options for patients, and genetic mutations, as opposed to disease sites, are at the forefront of drug development.  

    March 19, 2019
    What Does the Research Say About Genetic Testing and Underserved Populations?
    Research

    What Does the Research Say About Genetic Testing and Underserved Populations?

    Underserved communities largely have low rates of cancer genetic testing. Although the reasons vary, they can include lack of referrals, no or underinsurance, prohibitive cost, lack of trust, lack of knowledge, discrimination issues, or competing health needs.

    March 11, 2019
    Emily Edelman, MS, CGC, is the associate director of clinical and continuing education at the Jackson Laboratory in Bar Harbor, ME.
    Genetics & genomics

    How Do You Address Unanticipated Genomic Testing Results?

    Genomic testing—identifying variants, like mutations, in tumor cells to inform patient treatment options—occasionally comes with unanticipated results that clinicians have to address with their patients. Clinicians and patients alike are often hopeful that tumor genomic testing will identify a personalized cancer treatment. Indeed, many patients have benefited from being candidates for new targeted therapies identified through genomic testing. 

    March 05, 2019
    Testing in the Era of Precision Oncology
    Targeted therapy

    Testing in the Era of Precision Oncology

    Every cancer diagnosis is as individualized and unique as the person receiving it. From family history to societal and economic background to a patient’s genetic make-up and composition, cancer affects each person with cancer differently. Initiatives like precision medicine are based in data that suggest that a personalized disease should have its own personalized treatment. As a subset of precision medicine, precision oncology assesses a patient’s unique genetic profile to help align targeted therapies to hit the right cancer subtypes. 

    March 05, 2019
    Epigenetic Cervical Cancer Test May Be More Accurate Than Pap or HPV Tests
    Genetics & genomics

    Epigenetic Cervical Cancer Test May Be More Accurate Than Pap or HPV Tests

    An S5 methylation test detected 100% of grade 2 cervical intraepithelial neoplasms or worse, compared to a 50% detection rate for Pap or human papillomavirus (HPV) tests, according to the results of a recent study reported in the International Journal of Cancer.

    February 13, 2019
    BRCA Is Not the Only Common Mutation for Breast and Ovarian Cancer
    Research

    BRCA Is Not the Only Common Mutation for Breast and Ovarian Cancer

    Multigene testing for hereditary breast and ovarian cancer has increased the detection predisposition genes beyond BRCA1 and BRCA2, according to study findings presented at the San Antonio Breast Cancer Symposium on December 7, 2018. 

    January 02, 2019
    San Antonio Breast Cancer Symposium

    Trastuzumab Remains Standard HER2+ Breast Cancer Therapy Despite Cardiac Risks

    Trastuzumab can improve disease-free survival (DFS) and overall survival (OS) in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Although some studies suggest that short-term treatment (less than one year) may reduce cardiac toxicity and cost without compromising outcomes, the results of a new study presented at the San Antonio Breast Cancer Symposium on December 8, 2018, disagree.

    December 10, 2018
    San Antonio Breast Cancer Symposium

    On-Treatment Genetic Testing Improves Accuracy of Tumor Response Prediction

    Genetic testing during treatment can improve accuracy of response and outcome prediction compared to other prognostic tests, according to results from a study assessing on-treatment changes in gene expression in patients receiving chemotherapy. Researchers from Oikonomidou O Institute of Genetics and Molecular Medicine in Edinburgh, United Kingdom, presented the findings at the San Antonio Breast Cancer Symposium on December 6, 2018.

    December 06, 2018
    American Society of Hematology Annual Meeting

    Genetics Plays a Role in Treatment Response for Relapsed or Refractory Multiple Myeloma

    No molecular-informed personalized therapies are currently available for patients with relapsed/refractory multiple myeloma (MM); however, cytogenetics and next-generation sequencing (NGS) can identify molecular abnormalities to provide guidance for more targeted therapy. Tarek Assi, MD, of Gustave Roussy Cancer Campus in Villejuif, France, discussed his research team’s findings that tumor genotyping is associated with higher response rates and prolonged duration of therapy at the ASH Annual Meeting on December 1, 2018.

    December 01, 2018
    FDA Approves Larotrectinib for Solid Tumors With NTRK Gene Fusions
    U.S. Food and Drug Administration (FDA)

    FDA Approves Larotrectinib for Solid Tumors With NTRK Gene Fusions

    On November 26, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to larotrectinib for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment.

    November 27, 2018
    Which Gene is Associated With Cowden Syndrome (Multiple Hamartoma Syndrome)?
    Genetics & genomics

    Which Gene Is Associated With Cowden Syndrome (Multiple Hamartoma Syndrome)?

    Which Gene is Associated With Cowden Syndrome (Multiple Hamartoma Syndrome)?

    A. APC 

    B. VHL 

    C. TP53 

    D. PTEN

    October 05, 2018
    Biosimilars and Gene Therapy Are Making Great Strides in Cancer Care
    U.S. Food and Drug Administration (FDA)

    Biosimilars and Gene Therapy Are Making Great Strides in Cancer Care

    As researchers learn more about how combination therapy combats drug resistance and lessens the changes of tumor evasion of the immune system, immune checkpoint inhibitors are receiving approval for a broader range of indications. However, recent U.S. Food and Drug Administration (FDA) approvals have centered around hematologic malignancies and the emergence of two new biosimilars. 

    September 25, 2018
    How Patients Can Benefit From Hereditary Cancer Support
    Genetics & genomics

    How Patients Can Benefit From Hereditary Cancer Support

    My story, like many of your patients, is unfortunately not that uncommon: I’m a motherless daughter. I lost my mom to breast cancer when I was 26 years old; she lost her mother to the disease before she graduated high school. The BRCA1 mutation has been passed down in my family, and I, too, carry the mutation. Even though it was expected, I was devastated and desperately looking for resources to help manage my cancer risk. It was scary not knowing where to turn. I needed to know that I wasn’t alone. 

    September 18, 2018
    NINR Study Identifies Genes for Fatigue in Cancer Treatment
    Genetics & genomics

    NINR Study Identifies Genes for Fatigue in Cancer Treatment

    Radiation therapy can be an incredibly draining form of treatment for patients with cancer. Side effects such as fatigue can be debilitating for many before, during, and after treatment. Because symptom management is a crucial component to cancer care and central role of oncology nursing, ensuring that patients are able to mitigate their symptoms and side effects can help improve their quality of life. Recently, a team at the National Institute of Nursing Research (NINR) identified certain genes associated with fatigue in men being treated for prostate cancer.

    August 29, 2018
    ONS Congress

    Genomics Is Revolutionizing Cancer Care Now and For the Future

    As precision oncology continues to expand, so does the ability to use less-toxic targeted therapies. James Chen, MD, assistant professor of biomedical informatics and assistant professor of internal medicine at the division of medical oncology at Ohio State University in Columbus, described his work with genomics in cancer care and the challenges in precision medicine at the 43rd Annual Congress in Washington, DC.

    July 11, 2018
    Why Pretesting Counseling Is Critical in the Age of Consumer Genetic Tests
    Genetics & genomics

    Why Pretesting Counseling Is Critical in the Age of Consumer Genetic Tests

    On March 6, 2018, 23andMe—an at-home genetic testing company—announced their direct-to-consumer genetic test (DTCGT) would include DNA results for the three common founder BRCA mutations commonly seen in people with Ashkenazi Jewish ancestry. This was big news because DNA results for the BRCA mutations had been previously available on the 23andMe panel report until the U.S. Food and Drug Administration removed them in 2013.

    July 06, 2018
    New Gene-Based Tests Screen and Monitor for Bladder, Endometrial, and Ovarian Cancers
    Genetics & genomics

    New Gene-Based Tests Screen and Monitor for Bladder, Endometrial, and Ovarian Cancers

    Researchers have developed two new gene-based tests that detect DNA mutations that lead to bladder, endometrial, and ovarian cancers. The tests, which are not yet U.S. Food and Drug Administration approved, could be used to identify a new or relapsed cancer earlier, when it is easier to treat.

    June 27, 2018
    ASCO Annual Meeting

    Study Gives a Better Understanding of ARID1A Mutations in Colorectal Cancer

    A component of the SWI/SNF chromatin remodeling complex, AT-rich interactive domain 1A (ARID1A), regulates gene expression. Data on the characteristics and associated clinicopathologic features of ARID1A in colorectal cancer (CRC) are limited, even though its mutations are reported in a variety of other cancers. In study findings presented at the 2018 American Society of Clinical Oncology Annual Meeting, researchers explained an increased understanding of the ARID1A mutation in CRC.

    June 03, 2018
    • Current page 1
    • Page 2
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Oncology nurse influence
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2021 Oncology Nursing Society
     
    Back to Top ▲